Retension Pharmaceuticals, Inc.
NNASDAQ:RTSN15.01
USD
+0.01
(+0.07%)
CIK
2002988
ISIN
US76135H1005
CUSIP
76135H100
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Eric L. Keller
- Full Time Employees
- 12
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1104 West Broad Street 1029 Falls Church VA United States 22046
- IPO Date
- Oct 9, 2026
- CIK
- 0002002988
- Website
- retensionpharmaceuticals.com
- Similar Companies
- Business
- Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Company News
Retension Pharmaceuticals Announces Pricing of Initial Public Offering